NEFH

Across TCGA pan-cancer cohorts, NEFH Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NEFH data layer compared with 19 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NEFH Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NEFH expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, LUSC, and BLCA are the cancer types where NEFH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.045	0.717	<.001	32	view →
LUSC	DFS	Median	III,IV	0.010	0.754	<.001	24	view →
BLCA	DFS	Median	III,IV	1.000	0.426	.013	20	view →
SARC	OS	Median	All	0.085	0.839	<.001	12	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NEFH–LUAD (DFS)

Open the LUAD breakdown →